HHS cancels funding for Moderna’s candidate H5 avian flu and pandemic vaccines

In a startling pandemic preparedness development, Moderna yesterday announced that the US Department of Health and Human Services (HHS) has terminated a $590 million award it received in January for late-stage development of a candidate mRNA vaccine against H5 avian influenza and the development of other prepandemic vaccine candidates.

In the same announcement, Moderna reported positive interim phase 1/2 clinical data for its candidate vaccine targeting H5 avian influenza

https://www.cidrap.umn.edu/avian-influenza-bird-flu/hhs-cancels-funding-...